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Granzyme A Initiates an Alternative Pathway
for Granule-Mediated Apoptosis
receptor engagement leads to activation of the cas-
pases, which ultimately cleave substrates that are criti-
cal for the induction of apoptosis (Enari et al., 1996,
Sujan Shresta, Timothy A. Graubert,
Dori A. Thomas, Sofia Z. Raptis,
and Timothy J. Ley*
Division of Bone Marrow Transplantation 1998; Liu et al., 1997).
and Stem Cell Biology The precise role of perforin in the granule exocytosis
Department of Internal Medicine and Genetics pathway is not completely understood. Perforin is pro-
Washington University Medical School cessed and polymerizes upon exposure to calcium.
St. Louis, Missouri 63110 Polyperforin is capable of inducing damage to mem-
branes that causes the release of proteins from target
cells (e.g., 51Cr release). Although this membrane dam-
age can induce target cell necrosis, perforin alone is notSummary
sufficient to cause the apoptosis of nucleated cells in
vitro (Duke et al., 1989; Shi et al., 1992a, 1992b; ShiverGranzyme (gzm) B±deficient cytotoxic lymphocytes
et al., 1992). Recently, several investigators have ques-(CTL) have a severe defect in the rapid induction of
tioned the role of polyperforin molecules as ªentry sitesºtarget cell apoptosis that is almost completely cor-
for gzms (Shi et al., 1996; Jans et al., 1996; Pinkoskirected by prolonged incubation of the CTL effectors
et al., 1998; Froelich et al., 1998). They have insteadand their targets. We show in this report that perforin-
suggested that gzms may enter target cells in a perforin-dependent, gzmB-independent cytotoxicity is caused
independent manner, where they reside in a protectedby gzmA (or tightly linked genes). CTL deficient for
cytoplasmic compartment; perforin then acts to releasegzmA and gzmB retain normal perforin function, but
these CTL have a cytotoxic defect in vivo that is as the gzms from this protected compartment, allowing
severe as perforin-deficient CTL. Collectively, these them to translocate to the nucleus, where they cleave
results suggest that perforin provides target cell ac- critical death substrates. Regardless, both hypotheses
cess and/or trafficking signals for the gzms, and that suggest that perforin is required for the gzms to gain
the gzms themselves deliver the lethal hits. The gzmA access to their apoptotic substrates in the target cell.
pathway appears to function independently from gzmB A variety of in vitro studies have suggested that gran-
and may therefore provide a critical ªback-upº system zymes A and B (gzmA and and gzmB) are important for
when gzmB is inhibited in the target cell. the induction of target cell apoptosis (Pasternak and
Eisen, 1985; Hudig et al., 1991; Shi et al., 1992a, 1992b;
Nakajima et al., 1995). GzmB is thought to be a rapidly
Introduction acting apoptotic enzyme, while gzmA is thought to be
slow acting (Shi et al., 1992a, 1992b). CTL derived from
Cytotoxic lymphocytes are armed with two major con- mice deficient for gzmB have a severe defect in the
tact-dependent mechanisms for inducing apoptosis in rapid induction of apoptosis, but this defect is almost
their targets. The first is the granule exocytosis pathway, completely corrected by prolonged incubation of the
which is predominantly utilized by CD81 cytotoxic T effectors and targets (Heusel et al., 1994; Shresta et al.,
lymphocytes (CTL), natural killer cells (NK), and lympho- 1995). CTL derived from mice deficient for gzmA have
kine-activated killer cells (LAK). After these cytotoxic no detectable defect in cytotoxicity in vitro (Ebnet et al.,
lymphocytes conjugate with target cells, their cytotoxic 1995; Shresta et al., 1997a), but they do display a defect
granules vectorally migrate toward the site of contact, in the clearance of the orthopoxvirus Ectromelia (Mull-
followed by secretion of granule contents into the space bacher et al., 1996).
between the effector and the target cell (Henkart, 1994). In this report, we characterize mice that are deficient
In the classic model, granule-associated perforin cre- for both gzmA and gzmB. As previously reported (Pham
ates a pore in the target cell membrane through which et al., 1996), the gzmB loss-of-function mutation used
other granule constituents pass; the most abundant of here causes loss-of-function for gzms C, D, and F, which
the granule proteins are the granzymes (gzms), which lie just downstream from gzmB in a multi-gene cluster;
are neutral serine proteases that have the ability to in- this ªcluster knockoutº probably is caused by the re-
duce apoptosis upon target cell entry (Henkart, 1994; tained PGK-neo cassette in the gzmB gene. The gzmA
Shresta et al., 1998). The other major contact-mediated
and -B cluster-deficient mice have a defect in both the
cytotoxic mechanism is the Fas system, which is pre-
rapid and slow induction of cytotoxicity that is similar
dominantly used by CD41 T cells (Rouvier et al., 1993).
to perforin-deficient mice. However, these mice have
After T cell receptor engagement, the Fas ligand gene
normal quantities of fully functional perforin, suggestingis activated, and the newly synthesized Fas ligand is
that the membrane damage caused by perforin is insuffi-displayed on the surface of CTL, where it can interact
cient to cause target cell death in vitro or in vivo. Collec-with Fas receptor on the surface of the target cell. Fas
tively, our results suggest that perforin facilitates gzm
entry and/or trafficking, and that gzmB rapidly delivers
the lethal hit to the target cell. In the absence of func-* To whom correspondence should be addressed (e-mail: timley@
im.wustl.edu). tional gzmB, gzmA plays a critical role in the induction
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and fertility and are physically indistinguishable from
their wild-type counterparts.
Flow cytometric analyses of cells derived from the
thymus, lymph node, and spleen revealed normal hema-
topoiesis and lymphopoiesis in the gzmA2/2 3 gzmB2/2
mice (data not shown). Splenocytes from these mice
(H-2b) were stimulated with allogeneic BALB/c spleno-
cytes (H-2d) in a primary, one-way mixed lymphocyte
reaction (MLR) to generate allo-specific (H-2b anti-H-2d)
CTL or with high-dose IL-2 to generate LAK cells. As
expected, Western analysis using specific anti-gzmA
or anti-gzmB antisera revealed a complete absence of
gzmA and gzmB proteins in both MLR-CTL (data not
shown) and LAK cells (Figure 1) derived from the doubly
mutant mice.
GzmA2/2 3 GzmB2/2 Cytotoxic Lymphocytes
Have a Normal Ability to Proliferate
and Become Activated In Vitro
We detected no difference in the number of MLR-CTL
and LAK cells that could be generated from wild-type
Figure 1. Lack of GzmA or GzmB Protein in Cytotoxic Lymphocytes
or gzmA2/2 3 gzmB2/2 mice, indicating that these sple-Derived from GzmA2/2 3 GzmB2/2 Mice
nocytes can proliferate normally in response to alloge-Whole-cell extracts were prepared from 1 3 106 LAK cells derived
neic or IL-2 stimuli in vitro. Moreover, flow cytometricfrom wild-type (WT), gzmA2/2 (A2/2), gzmB2/2 (B2/2), gzmA2/2 3
analyses demonstrated nearly equivalent percentages ofgzmB2/2 (AB2/2), and perforin2/2 (P2/2) mice. Recombinant gzmA
(MA) (0.2 mg) and gzmB (MB) (0.1 mg) were prepared from superna- CD31, CD41, and CD81 cells in MLR cultures derived
tants of P. pastoris cultures. Proteins were analyzed via Western from wild-type, gzmA2/2 3 gzmB2/2, and perforin2/2
blotting using a previously described (Shresta et al., 1995) rabbit mice (Figure 2A), which were used for comparisons in
anti-murine gzmB antiserum (B) and a rabbit anti-mouse gzmA anti-
functional studies (discussed below). Additional flow cy-serum (A). Samples in both panels were prepared using denaturing
tometric studies revealed similar percentages of CD31,conditions; therefore, both gzmA and gzmB monomers recognized
CD41, CD81, CD161, and NK1.11 cells in LAK popula-by these antisera migrated at approximately 30 kDa. The position
of gzmA is shown by the arrow in (A), and the position of gzmB is tions from 129/SvJ wild-type versus gzmA2/2 3 gzmB2/2
shown by the arrow in (B). The heterogenous bands represent differ- mice, whereas the proportion of NK1.11 cells was con-
ent glycosylated forms of these enzymes. siderably higher in LAK cultures from perforin2/2 mice,
which were created in a mixed (C57BL/6 3 129/SvJ)
strain (Figure 2B); this result is expected, since NK cells
of apoptosis. The gzmA pathway may therefore be im- derived from the C57BL/6 strain express NK1.1, while
portant for CTL-mediated killing of target cells that con- 129/SvJ NK cells do not (Sentman et al., 1989). Regard-
tain inhibitors of gzmB. less, wild-type and gzmA2/2 3 gzmB2/2 effectors both
expand in cultures in a similar fashion.
Results
GzmA2/2 3 GzmB2/2 Cytotoxic Lymphocytes Retain
an Intact Perforin Pathway for InducingCharacterization of GzmA2/2 3 GzmB2/2 Mice
In our previous studies, cytotoxic lymphocytes derived Target Cell Membrane Damage
We examined the ability of gzmA2/2 3 gzmB2/2 effectorsfrom H-2b mice (C57BL/6 3 129/SvJ) carrying a homozy-
gous null mutation in the gzmA gene or gzmB gene to trigger membrane damage via perforin molecules: we
focused on LAK cells, since they contain more perforinwere shown to lack gzmA or gzmB mRNAs, respectively
(Heusel et al., 1994; Shresta et al., 1997a). Further stud- than MLR-CTL. As shown in Figure 3A, a Western analysis
of LAK extracts revealed equivalent amounts of perforinies demonstrated that effector cells from gzmA2/2 mice
did not show any reduction in the level of gzmK mRNA (with the same electrophoretic mobility) in wild-type and
gzmA2/2 3 gzmB2/2 samples, further confirming the ac-(Shresta et al., 1997a), whereas LAK cells from gzmB2/2
mice demonstrated markedly decreased expression of tivation status of these cells, since perforin expression
is restricted to activated CTL. We then tested the mem-downstream gzmB-cluster genes C through G, presum-
ably due to a ªneighborhood knockoutº effect of the branolytic activity of these extracts using hemolytic
assays in which the amount of hemoglobin releasedPGK-neo cassette retained in the mutant alleles (Pham
et al., 1996). In the present study, we rederived these from sheep red blood cells is measured spectrophoto-
metrically. As shown in Figure 3B, perforin2/2 LAK cellgzmB2/2 and gzmA2/2 mice into the 129/SvJ strain (H-2b)
and mated them with each other to obtain doubly hetero- extracts have no ability to disrupt sheep red blood cell
membranes, demonstrating that this assay is perforin de-zygous mutants. Southern analysis of tail DNA derived
from the progeny of doubly heterozygous matings re- pendent. In contrast, wild-type and gzmA2/2 3 gzmB2/2
LAK cell extracts demonstrate the same dose-depen-vealed an expected number of doubly homozygous mice
(data not shown); these mice have normal development dent ability to cause sheep red cell membrane damage.
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Figure 2. Normal Proliferation and Activation
of Cytotoxic Lymphocytes Derived from
GzmA2/2 3 GzmB2/2 Splenocytes
Day 5 MLR cells (A) and high-dose IL-2-stimu-
lated LAK cells (panel B) derived from wild-
type (WT), gzmA2/2 3 gzmB2/2 (AB2/2), and
perforin2/2 (P2/2) mice were analyzed by flow
cytometry. The expression profiles of cells
stained with FITC-labeled monoclonal anti-
bodies specific for mouse CD3, CD4, CD8,
CD16, PE-labeled NK1.1 (filled histograms)
were overlaid with background fluorescence
of cells stained with isotype control antibod-
ies (open histograms). The percentages of
cells within the gated windows was similar
for all mice.
This result indicates that gzmA2/2 3 gzmB2/2 LAK cells (Figure 2A), allowing us to directly compare their cyto-
toxic activities.contain normal amounts of fully functional perforin.
The cytotoxic activity of MLR-CTL against allogeneic
TA3 (H-2d) cells is shown in Figure 4. After 2 hr of incuba-GzmA2/2 3 GzmB2/2 Cytotoxic Lymphocytes Have
a Severe Defect in Their Ability to Induce Target tion, perforin-deficient CTL induce no 51Cr release from
the target cells; gzmA2/2 3 gzmB2/2 CTL mediate lessCell DNA Fragmentation after Prolonged
Incubation with Allogeneic Target Cells 51Cr release than wild-type CTL, but this defect varies
among experiments for reasons that we do not yet un-We examined the function of gzmA2/2 3 gzmB2/2 ef-
fector cells using standard cytotoxicity assays, in which derstand (Heusel et al., 1994). After 8 hr of incubation,
both wild-type and gzmA2/2 3 gzmB2/2 CTL reproduc-51Cr or 125IUdR release was measured as a function of
increasing E:T (effector:target) ratios against a fixed ibly induce equivalent 51Cr release from their targets,
while perforin2/2 CTL remain defective. As expected,number of radiolabeled target cells; the effectors and
targets were coincubated for 2 hr (ªearlyº) or 8 hr (ªlateº). MLR-CTL derived from all three types of mice caused
no 51Cr (or 125IUdR release) from syngeneic EL4 (H-2b)We conducted these experiments using MLR-CTL in-
stead of LAK cells for two reasons. First, we were able target cells (data not shown). Therefore, both the 51Cr
release and hemolytic assays suggest that the gzmA2/2 3to test MLR-CTL against three different allogeneic target
cell lines (TA3, P815, and YAC1), whereas we have only gzmB2/2 CTL are equipped with functional perforin.
The 125IUdR release assays (right panels in Figure 4)one reliable LAK-sensitive target cell line (YAC1). Sec-
ond, as shown in Figure 2B, the NK1.11 LAK cells from demonstrate that gzmA2/2 3 gzmB2/2 CTL are very simi-
lar to perforin2/2 CTL in their inability to induce targetC57BL/6 3 129/SvJ perforin2/2 mice are probably not
appropriate controls for the NK1.12 LAK cells derived cell DNA fragmentation. GzmA2/2 3 gzmB2/2 CTL com-
pletely lack the ability to cause 125IUdR release fromfrom 129/SvJ wild-type or gzmA2/2 3 gzmB2/2 mice.
MLR cultures from all three types of mice contained target cells after 2 hr of incubation. This defect is entirely
due to the gzmB mutation (Heusel et al., 1994). Per-relatively equal proportions of appropriate T cell subsets
Immunity
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ªneighborhoodº effects. Although the expression pat-
terns of the known neighboring genes in both the gzmA
and gzmB loci have already been reported, possible
effects of other unidentified genes in the neighborhood
cannot be ruled out, since the gzmA and gzmB clusters
have not yet been fully characterized. Therefore, to de-
termine whether gzmA and gzmB themselves were re-
sponsible for the defects observed in the gzmA2/2 3
gzmB2/2 effectors, we developed recombinant gzms for
use in 125IUdR release assays to reconstitute the missing
enzymes in these cells (Pham et al., 1998).
Figure 5 depicts the results of reconstitution assays
using LAK cells incubated for 2 hr with YAC1 targets at
a fixed E:T ratio of 30:1 (E 5 3 3 105 cells; T 5 104 cells).
We previously demonstrated that the specific activity
of recombinant murine gzmB is at least as great as that
of native gzmB purified from wild-type LAK cells (Pham
et al., 1998). Similarly, equal amounts of recombinant
gzmA and native gzmA from wild-type LAK cells had
equivalent BLT-esterase activity (data not shown). We
performed Western analyses of whole-cell extracts pre-
pared from known numbers of wild-type LAK cells and
known amounts of the recombinant gzms; these blots
revealed the relative amounts of recombinant enzyme
added with respect to the native enzyme present in a
fixed dose of wild-type LAK cells (Figure 5A). Densito-
metric analysis revealed that 3 3 105 wild-type LAK cells
Figure 3. Normal Expression and Activity of Perforin in GzmA2/2 3 contained approximately 0.13 mg of gzmB and 0.24 mg
GzmB2/2 LAK Cells of gzmA. These data suggest that the gzms comprise
(A) LAK cell extracts (50 mg) derived from wild-type (WT), gzmA2/2 3 several percent of the wet weight of LAK cells, consis-
gzmB2/2 (AB2/2), and perforin2/2 (P2/2) mice were analyzed by West-
tent with previous reports (Masson and Tschopp, 1987;ern blotting. The rat monoclonal antibody directed against mouse
Poe et al., 1991). The recombinant gzms were used atperforin detected similar amounts of the 60 kDa perforin protein in
amounts ranging from 0.5 mg to 2.0 mg per 100 ml reac-WT and AB2/2 samples. The position of correctly processed perforin
is shown by the arrow. The absence of perforin in the P2/2 lane tion; these doses do not alter the normal ability of wild-
confirmed the specificity of this antibody. type LAK cells to induce 125IUdR release from their tar-
(B) Wild-type (WT), gzmA2/2 3 gzmB2/2 (AB2/2), and perforin2/2 gets (Figure 5B).
(P2/2) LAK cell extracts were assayed for hemolytic activity against
Perforin-deficient LAK cells are completely defectivesheep red blood cell membranes. The amount of hemoglobin re-
in their ability to induce 125IUdR release with or withoutleased into the red cell supernatants was spectrophotometrically
added gzms (Figure 5B). Recombinant gzmB, but notmeasured at 405 nM. OD405 values (y-axis) were plotted against
increasing amounts of LAK cell extracts (x-axis). Similar results were gzmA, partially restores the ability of gzmA2/2 3
obtained in four independent experiments. gzmB2/2 LAK cells to mediate 125IUdR release in a dose-
dependent manner (left and middle panels in Figure 5B).
The effect of gzmB is specifically due to the active en-forin2/2 CTL are also completely defective for the early
induction of 125IUdR release, presumably because per- zyme, since equal amounts of an attenuated Ser183Ala
mutant form of recombinant gzmB did not induce 125IUdRforin is required to deliver gzmB to its intracellular tar-
gets. After 8 hr of incubation, the gzmA2/2 3 gzmB2/2 release (data not shown). Therefore, these results con-
firm that gzmB itself is at least partially responsible forand perforin2/2 CTL have the same severe defect in the
induction of 125IUdR release from target cells. This result the induction of target cell DNA fragmentation and that
gzmB activity in target cells requires perforin. The in-has been reproduced using two additional allogeneic
target cell lines (P815 and YAC1; data not shown). Impor- complete correction of target cell 125IUdR release by
gzmB may be due to the requirement for other tightlytantly, we have previously shown that neither gzmA2/2
nor gzmB2/2 CTL have substantial defects in the induc- linked gzms in the cluster (e.g., gzms C, D, and/or F) or
to an insufficient effective concentration of gzmB; wetion of 125IUdR release after 8 hr of incubation with their
targets (Heusel et al., 1994; Shresta et al., 1997a, 1997b). could not study the effect of gzmB at larger doses, since
these doses reduced 125IUdR release caused by wild-This result suggests that gzmA (or a tightly linked gene)
is responsible for the target cell DNA fragmentation type effectors.
GzmA did not induce 125IUdR release at any concentra-caused by gzmB2/2 CTL after prolonged incubation with
their targets. tion tested. The combination of both gzmA and gzmB
at equimolar concentrations had an effect similar to that
of gzmB alone (right panel in Figure 5B). At present,Recombinant GzmB Partially Reconstitutes the Ability
the role of gzmA for the induction of apoptosis afterof GzmA2/2 3 GzmB2/2 Cytotoxic Lymphocytes to
prolonged incubation cannot be biochemically con-Induce Target Cell DNA Fragmentation In Vitro
firmed, since the target cells undergo spontaneous apo-Since both the gzmA and gzmB mutant loci retain the
ptosis in the serum-free buffer system required to sup-PGK-neo cassette, the observed phenotype may be in-
fluenced by the downregulation of nearby genes due to port gzm activity for 8 hr of incubation (data not shown).
The Granzyme A Pathway
599
Figure 4. Cytotoxic Activity of GzmA2/2 3 GzmB2/2 MLR Cells
In vitro cytotoxicity of allospecific (H-2b anti-H-2d) MLR cells from wild-type (WT), gzmA2/2 3 gzmB2/2 (AB2/2), and perforin2/2 (P2/2) mice
was tested against the allogeneic (H-2d) TA3 target cells at increasing E:T ratios (3.75:1 to 30:1; T 5 104 cells) after 2 hr (top panels) and 8 hr
(bottom panels) of incubation of effector with target cells. Data are presented as mean 6 SEM of duplicate samples. The SEMs for most of
the data points are very small and are contained within the symbols. This experiment is representative of ten experiments with similar results.
GzmA2/2 3 GzmB2/2 and Perforin2/2 CD81 CTL while perforin2/2 CD81 T cells permitted 90% survival
Have Similar Defects in an Acute Graft in this model (Figure 6A; Graubert et al., 1997). In the
versus Host Disease Model present study involving the gzmA2/2 3 gzmB2/2 mice,
To evaluate the physiological significance of the in vitro wild-type CD81 T cells caused the death of all recipients
cytotoxic defects observed in gzmA2/2 3 gzmB2/2 CTL, within 55 days of the transplant, while perforin2/2 CD81
we used an acute GVHD model (Sprent et al., 1986; T cells again allowed .75% of the recipients to survive
Graubert et al., 1996, 1997) to examine the in vivo cyto- (P , 0.001) (Figure 6B). Similarly, CD81 T cells from
toxicity of CD81 T cells. In this model, the recipients are gzmA2/2 3 gzmB2/2 mice also allowed .80% of recipi-
(B6.C-H-2bm1 3 129/SvJ) F1 mice, which share all major ents to survive (P , 0.001) and were therefore indistin-
histocompatibility loci with 129/SvJ gzmA2/2 3 gzmB2/2 guishable from T cells derived from perforin2/2 mice
mice, except for a mutant H-2bm1 (class I) allele and minor (P 5 0.32) (Figure 6B). The median survival time of the
histocompatibility antigens; the mutant bm1 allele cre- recipients reconstituted with wild-type CD81 T cells was
ates a strong, class I±restricted allogeneic signal. These 38 days in this study versus 24 days in past studies,
recipients were lethally irradiated and then rescued with perhaps because of the lower CD81 T cell dose used
an infusion of syngeneic marrow combined with CD4- in this study, improved survival in our new barrier facility,
depleted, CD81 T cells obtained from the mesenteric or strain differences between the previous experiments
lymph nodes of sex-matched littermate wild-type mice, (C57BL/6 3 129/SvJ) and this one (129/SvJ). Each set
gzmB2/2 mice, gzmA2/2 mice, gzmA2/2 3 gzmB2/2 mice, of experiments was internally controlled in that the T
or perforin2/2 mice. Following recognition of the bm1 cell dose resulted in 100% mortality for the wild-type
signal on the recipient cells, wild-type T cells become group and .90% survival for the perforin2/2 group. This
activated and attack the bm11 hematopoietic cells in allows a meaningful comparison of the results for the
the graft, leading to death of the recipients from marrow gzm-deficient effectors between experiments.
failure; in contrast, CD81 T cells with defective cytotoxic-
ity do not destroy the graft, and the recipients can sur-
Discussionvive with normal hematopoiesis.
As previously reported (Graubert et al., 1996, 1997),
In this report, we describe the phenotype of gzmA2/2 3all mock-transplanted recipients died within 2 weeks
gzmB2/2 mice made in the 129/SvJ (H-2b) background.due to marrow aplasia (data not shown), while all mice
The evaluation of CTL derived from these mice has re-transplanted with marrow only and no T cells survived
vealed that the perforin-dependent cytotoxicity of gzmB2/2(Figure 6A). T cells derived from wild-type or gzmA2/2
mice can be accounted for by gzmA or a tightly linkedmice caused the death of all recipients within 30 days
gene. The relevance of gzmA for CTL function is alsoposttransplant (Figure 6A). In our previous studies, we
emphasized by the in vivo studies described in this re-demonstrated that gzmB2/2 CD81 T cells allowed a sig-
nificant number (20%±30%) of the recipients to survive, port, which demonstrate that gzmA plays a large role in
Immunity
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Figure 5. Partial Reconstitution of the Early Target Cell DNA Fragmentation Pathway in the GzmA2/2 3 GzmB Cluster2/2 LAK Cells by
Recombinant GzmB
(A) Total cell extracts from fixed numbers of wild-type LAK cells (WT) and known amounts of recombinant gzmA (MA) and gzmB (MB) were
analyzed by Western blotting using rabbit antisera against mouse gzmA (left panel) and mouse gzmB (right panel).
(B) A 2 hr 125IUdR release assay was performed using 3.0 3 105 LAK cells derived from wild-type (WT), gzmA2/2 3 gzmB2/2 (AB2/2), and
perforin2/2 (P2/2) mice and 104 YAC1 targets (E:T ratio 5 30:1; incubation time 5 2 hr). Recombinant mature gzmA (MA) and/or mature gzmB
(MB) were added into each mixture of effector and target cells. Three different amounts (0.5, 1.0, and 2.0 mg) of each recombinant enzyme
were used. Data are represented as mean 6 SEM of duplicate samples. Similar results were obtained in five separate experiments.
the overall cytotoxic potential of CD81 effectors. We In the present study, we characterized the abundance
and function of perforin in gzmA2/2 3 gzmB2/2 mice.have also shown here that effector cells armed with per-
forin but not with gzmA or gzmB cluster enzymes are Cytotoxic lymphocytes derived from these mice have
normal amounts of perforin of the correct size (Uellnerable to induce target cell membrane damage in in vitro
settings (frequently referred to as ªnecrosisº), but this et al., 1997), and lysates made from these cells have
normal levels of perforin activity in a sheep red blood cellmembrane damage does not lead to target cell death
in an in vivo model system. These results strongly sug- lysis assay that specifically measures perforin activity.
Similarly, we have shown that gzmA2/2 3 gzmB2/2 ef-gest that the membrane damage induced by perforin
does not directly cause target cell death; rather, perforin fectors induce 51Cr release from their target cells; 51Cr
release measures protein leakage caused by membranefacilitates the action of the death effector molecules,
the gzms. Our results also suggest that the gzmA and damage and is an assay that can be affected by multiple
pathways. However, early 51Cr release is due to perforin-gzmB loci contain most, if not all, of the death effector
machinery delivered to target cells via perforin. mediated events in the target cell (Kagi et al., 1994a;
Kojima et al., 1994; Lowin et al., 1994; Walsh et al., 1994),The results presented in this paper confirm and extend
the results reported by Simon and colleagues (1997), while at later time points, 51Cr release is caused not
only by perforin-induced damage but also by membranewho also evaluated the cytotoxicity of lymphocytes de-
rived from gzmA 3 gzmB deficient animals. The gzmA2/2 damage induced by internal disintegration of the cell
from the Fas pathway (Kagi et al., 1994b; Lowin et al.,mice in their study were made by inserting a PGK-neo
cassette into exon 4 of the gzmA gene; the genetic 1994; Braun et al., 1996; Shresta et al., 1997b). Both the
in vitro and in vivo studies described here show thatbackground of the gzmA2/2 mice was C57BL/6. The
gzmB2/2 mice were obtained from our laboratory and gzmA2/2 3 gzmB2/2 CTL have a severe defect in their
ability to cause target cell deathÐa defect that is similarwere created in a mixed 129/Sv 3 C57BL/6 background.
The gzmA mutation used in this study was made by in magnitude to the defect observed in perforin-deficient
CTL. These results confirm the observation that perforindeleting exon 2 of the gzmA gene, and the mutation
was made in 129/SvJ mice (Shresta et al., 1997a). We alone cannot kill target cells and suggest that the mem-
brane damage caused by perforin can be repaired byrederived the gzmB mutation in 129/SvJ mice for this
study so that the genetic background of all of the mice the target cells if the gzms are not delivered (Duke et
al., 1989; Shi et al., 1992a, 1992b; Shiver et al., 1992).is identical. Regardless, the results of the in vitro cyto-
toxicity assays between the two studies are similar. No consistent cytotoxic defect has been detected in
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Figure 6. The Phenotypes of GzmA2/2 3
GzmB2/2 and Perforin2/2 CD81 Effector Cells
Are Similar in an Acute Graft versus Host Dis-
ease Model
(A) Phenotype of CD81 T cell effectors from
mice deficient for gzmA or gzmB. Bm1 3 129/
SvJ recipient mice were lethally irradiated
and were then reconstituted with 2 3 106 syn-
geneic bone marrow cells mixed with 1 3 106
class I±mismatched CD81 T cells from wild-
type (WT), perforin2/2 (P2/2), gzmA2/2 (A2/2),
or gzmB cluster2/2 (B2/2) mice. The Kaplan-
Meier plot demonstrates that survival from
graft-versus-host disease was similar when
gzmA2/2 CD81 T cells (n 5 8) were infused,
as compared to wild-type CD81 T cells (n 5
7). Survival was significantly prolonged when
gzmB cluster2/2 CD81 T cells were used (n 5
16) (p , 0.01). When perforin2/2 CD81 T cells
were used (n 5 15), survival was indistin-
guishable from control transplants using syn-
geneic marrow without T cells (n 5 4). Data
for this curve were pooled from three indepen-
dent experiments, each of which had a similar
outcome. The results for the perforin2/2 and
gzmB2/2 mice have been previously pub-
lished (Graubert et al., 1997) and are shown
for comparison.
(B) Phenotype of CD81 T cell effectors from
gzmA2/2 3 gzmB2/2 versus perforin2/2 mice.
Class I±mismatched transplants were per-
formed as described in (A), except that 1.5 3
105 CD81 cells were infused. The Kaplan-
Meier plot shows that z75% of recipients re-
constituted with CD81 T cells from either
gzmA2/2 3 gzmB2/2 (n 5 11) or perforin2/2
(n 5 11) mice survived. As expected, all recip-
ients with wild-type CD81 T cell donors (n 5
11) died. Data for this curve were pooled from
three independent experiments, each of
which had a similar outcome.
vitro with gzmA-deficient mice generated by either our We and others have recently been able to successfully
express fully active recombinant gzms using differentgroup (Shresta et al., 1997a) or by Simon and colleagues
(Ebnet et al., 1995). However, the role of gzmA for cyto- approaches (Beresford et al., 1997; Harris et al., 1998;
Pham et al., 1998; Xia et al., 1998). The reconstitutiontoxic lymphocyte-mediated function is clearly demon-
strated in the gzmA 3 gzmB deficient mice. The previous assay described in this report relies upon the ability
of the recombinant gzms to enter the target cell via astudies of Shi and colleagues (1992b) and Shiver and
colleagues (1992) strongly suggested that gzmA was perforin-dependent mechanism. Large absolute ex-
cesses of recombinant gzmB can partially, but not com-important for CTL-mediated cytotoxicity, and Nakajima
et al. (1995) suggested that it could somehow synergize pletely, correct the cytotoxic defect observed with
gzmA2/2 3 gzmB2/2 effector cells; this effect is depen-with gzmB to effect apoptotic death. Our results extend
those landmark studies. GzmA is extremely important dent on the proteolytic activity of gzmB, since an equal
amount of an attenuated version of recombinant gzmBfor CD81 and LAK-mediated cytotoxicity in vitro and in
vivo, but the effect of gzmA deficiency is masked by an was inactive in this assay. This result clearly proves that
at least part of the phenotype of the gzmB mutation isintact gzmB pathway in the gzmA2/2 mice. Although
gzmB2/2 CTL have a profound defect in the rapid induc- due to deficiency of gzmB itself. However, the partial
reconstitution leaves open the possibility that the ex-tion of apoptosis in their targets, this defect is almost
completely corrected by prolonged incubation of the pression of additional genes within the cluster (e.g.,
gzms C, D, or F) are required for the full reconstitutioneffectors and targets (Heusel et al., 1994; Shresta et al.,
1995a). Some of this ªcorrectionº is provided by the Fas of early cytotoxicity. To address this question, we have
developed mice that contain a null mutation of gzmBsystem, and the rest is perforin dependent (Shresta et
al., 1997b). The perforin-dependent component is clearly only by removing the PGK-neo cassette from the mutant
locus using Cre-recombinase mediated excision. Thedue to gzmA (or a tightly linked gene) both in vitro and in
vivo. These results suggest that gzmA plays an essential preliminary analysis of these mice suggests that gzmB
itself is responsible for the rapid induction of apoptosisrole in CTL cytotoxicity only when effectors lack gzmB
or when target cells contain inhibitors of gzmB, as dis- in vitro (D. A. T. and T. J. L., unpublished data).
Alternatively, the partial reconstitution may reflect thecussed below.
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inefficiency of the assay system; we are adding z5- to
20-fold molar excesses of recombinant gzms compared
to the amount present within the defined number of wild-
type effectors used in the assay. However, the ªeffective
concentrationº of the recombinant gzms may be quite
low; the effector cell gzms are highly concentrated
within the granules of these cells and are delivered pre-
cisely to the target cells after a tight junction is estab-
lished. The extracellular, recombinant gzms used in this
assay may enter target cells through pores in the target
cell membrane created by perforin or may enter via a
nonperforin-dependent mechanism. This delivery mecha-
nism may be very inefficient and may explain why we
cannot completely correct the cytotoxic defect with ex-
ogenous enzyme.
We were not able to assess the role of gzmA in the
reconstitution assay with prolonged incubations, be-
cause the target cells underwent spontaneous apopto-
sis in the serum-free buffer that was required to maintain
gzm activity in these assays. However, we did learn that
gzmA cannot substitute for gzmBÐnor synergize with
itÐin the 2 hr reconstitution assay; these results strongly
suggest that gzmA must induce apoptosis via a non-
overlapping mechanism from gzmB. Gzm B is an aspase
(Odake et al., 1991; Thornberry et al., 1997; Harris et
al., 1998) that is known to cleave and activate several
procaspases upon target cell entry (Darmon et al., 1995,
1996; Martin et al., 1996; Quan et al., 1996; Talanian et
al., 1997); however, the requirement of caspase activa-
tion for the induction of target cell apoptosis remains
Figure 7. A Model for the GzmA and GzmB Pathwayshighly controversial (Sarin et al., 1997; Talanian et al.,
This model suggests that the gzmA pathway is independent from1997; Andrade et al., 1998). One biochemical substrate
gzmB, even though these pathways could potentially converge onfor gzmA (a tryptase) has been identified (pHAP-2)
common substrates (indicated by overlapping circles). The gzmA
(Beresford et al., 1997), but the physiologic substrates pathway induces target cell apoptosis slowly, either because this
of gzmA in the apoptosis pathway are completely un- enzyme is kinetically slow (indicated by the corkscrew) or because
known. Furthermore, we do not know whether gzmA it acts through multiple substrates before the apoptotic substrates
are reached (indicated by the multiple arrow pathway). Regardless,and gzmB cause apoptosis by activating the same distal
the gzmA pathway cannot be detected unless the gzmB pathwayapoptotic substrates.
is inactivated, either by a loss-of-function mutation in the effectorCollectively, these results suggest a model for how
cell (e.g., gzmB2/2 mice) or by inhibiting the activity of gzmB in thethe perforin-gzm system functions (see Figure 7). In this target cell. As an example, the poxvirus crmA gene encodes a serine
model, perforin is responsible for gaining entry into the proteinase inhibitor (serpin) that interacts with and inhibits the activi-
target and delivering the molecules that cause the lethal ties of apoptotic caspases and gzmB. Under these circumstances,
hits. GzmB can be likened to a grenade that detonates gzmA may still be able to kill the target cell via an independent
apoptotic mechanism (see Discussion for details).almost immediately in the target. GzmA behaves like a
bomb with a delayed fuse. If gzmB can attack its critical
apoptotic substrates, the target cell is quickly killed; the
Why do CTL granules contain two distinct enzymesgzmA pathway cannot be detected under these circum-
for inducing apoptotic death in target cells? Our resultsstances, because it is destroyed in the dying cell. How-
suggest that the gzmA pathway may have evolved as aever, if gzmB fails to be delivered or is somehow inacti-
back-up pathway for gzmB in virus-infected cells (Smythvated in the target cell, the long-fused gzmA bomb can
and Trapani, 1998). Pickup and colleagues first identifiedstill ultimately kill the target. This model suggests that
a cowpox gene that encodes a serpin (serine proteinasegzms A and B do not synergize with each other in the
inhibitor) known as the cytokine response modifier Aclassic sense but provide two distinct, independent
(CrmA) protein (Ray et al., 1992). CrmA binds to andpathways that can each cause the apoptotic death of
inactivates caspases and also gzmB (Quan et al., 1995;the cell. This model does not explain why gzmB acts
Zhou et al., 1997); overexpression of CrmA in targetrapidly and why gzmA acts slowly. Gzm A may initiate
cells can inhibit the rapid induction of apoptosis by CTLapoptosis by activating an alternate pathway that has
(Tewari et al., 1995). Recently, Mullbacher and col-many protease components, akin to the complement
leagues demonstrated that the orthopoxvirus Ectro-pathway or the coagulation cascade. Alternatively, this
melia is cleared slowly in gzmA-deficient mice (Mull-enzyme may directly cleave critical apoptotic target pro-
bacher et al., 1996). Ectromelia contains a CrmAteins but at a slow rate. Regardless, the gzmA pathway
homolog (87% identical to CrmA), and therefore cellsis functional in the absence of gzmB, and it therefore
infected with this virus are probably resistant to gzmB-represents an alternate pathway for the induction of
apoptosis. induced apoptosis. Under normal circumstances, the
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tryptase activity after 4 days of induction was chosen to be ex-gzmA pathway is required to clear the virus, since gzmB
panded into 2L cultures. The day 4 supernatant of 2L cultures wasis inhibited; if gzmA is not present, the virus persists.
purified using an Accell Plus cation exchange column (Waters), asThese results predict that any virus that expresses a
previously described. The purity of recombinant gzmA, which eluted
functional inhibitor of gzmB might be cleared more at 0.70±0.75 M NaCl, was confirmed by silver staining (ICN Biomedi-
slowly in gzmA-deficient mice. Experiments to confirm cals). The expected monomeric (28±32 kDa) and homodimeric
(60±70 kDa) forms of gzmA were detected in reducing SDS-PAGEthis hypothesis are in progress.
and nonreducing gels, respectively.There are other circumstances where the gzmA path-
way may be important because of inhibition of the gzmB
Generation of Anti-Mouse GzmA Antiserumpathway. For example, parainfluenza virus type 3 infec-
Polyclonal rabbit antiserum against mouse gzmA was obtained by
tion can apparently reduce the abundance of gzmB immunizing rabbits (EL Labs) with recombinant gzmA protein that
mRNA in CTL (Sieg et al., 1995), which would reduce was purified as described above. The specificity of the antiserum
the delivery of gzmB to the target cell. Alternatively, was confirmed by comparing Western analysis of wild-type versus
gzmA2/2 effector cell lysates and recombinant mouse gzmA versusgzmB could potentially be inhibited in target cells by
recombinant mouse gzmB protein.cellular serpins (Sun et al., 1996; Hampson et al., 1997;
Bird et al., 1998) or inhibitor of apoptosis proteins (IAPs)
Western Blot Analysesrelated to the baculovirus p35 IAP (Hay et al., 1995;
Effector cell lysates, which were prepared via a freeze-thaw proce-
Rothe et al., 1995; Xue and Horvitz, 1995; Hawkins et dure (see below in Hemolytic Assays), and recombinant gzms were
al., 1996; Deveraux et al., 1997; Irmler et al., 1997). IAP analyzed using a standard Western blotting technique, and signals
expression has been detected in tumors and tumori- were detected by enhanced chemiluminescense via horseradish
peroxidase linked anti-rabbit or anti-rat Ig secondary antibodies atgenic cell lines (Irmler et al., 1997); inappropriate expres-
a 1:5000 dilution (Amersham Life Science). The primary antibodiession of IAPs could protect these cells from apoptotic
used were rabbit anti-mouse gzmA antiserum (described above) atstimuli delivered by a variety of apoptotic stimuli, includ-
a 1:1000 dilution, rabbit anti-mouse gzmB antiserum at a 1:1000
ing gzmB. If gzmA does not activate the same substrates dilution, and rat anti-mouse perforin monoclonal antibody (clone
targeted by the caspases and gzmB, its activity would P1±8) (Kamiya Biomedical Company) at 5 mg/ml.
not be inhibited by any of these molecules.
In summary, these results establish an important role Tryptase Activity Assays
The tryptase activity of recombinant and native gzmA was deter-for gzmA in cytotoxic effector cells and demonstrate that
mined using N-a-benzylcarbonyl-L-lysine thiobenzyl ester (BLT) asperforin-induced membrane damage does not cause
a substrate, as previously described (Shresta et al., 1997a).irreversible changes in target cells that cause their
death. The irreversible changes are caused by gzms A Effector Cells, Target Cells, and In Vitro Lytic Assays
or B (or tightly linked genes), which probably induce The production of effector cells, labeling of target cells, and perfor-
target cell death via independent apoptotic pathways; mance of in vitro lytic assays was previously described (Heusel et
al., 1994; Shresta et al., 1995).we do not know whether these pathways converge on
the same apoptotic substrate or different ones. Future
Hemolytic Assaysstudies will be directed toward the identification and
Sheep red blood cells (Clonetics) were washed and resuspendedcomparison of the key apoptotic pathways activated by
at 3 3 107 cell/ml in HBSS, 2 mg/ml BSA, 0.01 M HEPES (pH 7.4),
these very different enzymes. and 2.5 mM CaCl2. Freeze-thaw extracts of LAK cells were prepared
by washing cells twice in PBS, followed by resuspension at 107
Experimental Procedures cells/100 ml in PBS/1 mM EDTA, frozen in a dry ice/ethanol bath for
10 min, and thawed in a 48C bath. The resulting cell extracts were
Creation of GzmA2/2 3 GzmB Cluster2/2 Mice briefly sonicated, spun in a microcentrifuge to remove cellular de-
To obtain doubly deficient mice in a pure 129/SvJ (H-2b) background, bris, and the total protein concentration in the cleared lysate was
129/SvJ females were first mated with gzmA-chimeric chimeric quantitated using a Bio-Rad protein assay (Bio-Rad). Varying con-
males (obtained via injecting targeted RW4 embryonic stem [ES] centrations of the cell lysate (in a final volume of 50 ml PBS/1 mM
cells into C57BL/6 blastocysts) or with gzmB cluster±chimeric males EDTA) were mixed with 150 ml of the sheep red blood cell suspension
(obtained via injecting targeted D3 ES cells into C57BL/6 blasto- in a 96-well plate, and the plate was incubated for 20 min at 378C.
cysts). The resulting single heterozygotes were then intercrossed Following centrifugation of the plate, the amount of hemoglobin
to produce mice deficient for both gzmA and gzmB cluster prote- present in the supernatants was measured at A405 nM using a mi-
ases. All mutant mice used for the experiments in this report (includ- croplate reader (Molecular Devices).
ing perforin-deficient mice in a mixed C57BL/6 3 129/SvJ back-
ground) were identified by Southern blotting analysis of restriction In Vitro Reconstitution Assays
enzyme±treated tail DNA and were 6±12 weeks of age. Target cells were labeled with 125IUdR, and effector cells were har-
vested exactly as described for standard lytic assays (above). Next,
fetal calf serum was removed by washing both target and effectorProduction of Active Recombinant Murine GzmA
The cDNA encoding the mature form of mouse gzmA was PCR- cells in Hank's balanced salt solution (HBSS) three times, followed
by final resuspension in H5 medium (HBSS supplemented with 4amplified and subcloned into the pCR 2.1 vector (Invitrogen) using
the forward (59-CTCGAGAAAAGAATCATTGGAGGAGACACGGTTG mg/ml fatty acid free BSA, 2 mM CaCl2, and 10 mM HEPES [pH
7.4]). Target cells (104 in 50 ml H5), effector cells (3 3 105 in 50 mlTTCCTCACTCAAGACCG-39) and reverse (59-TTACACAGAACCC
TTC-39) primers, which add a XhoI site and the a-factor signal pep- H5), and 100 ml of recombinant gzms in HE buffer (10 mM HEPES
[pH 7.4], 140 mM NaCl, and 1 mM EGTA) were mixed together andtide sequence of Pichia pastoris at the 59 end of the cDNA. The
XhoI±EcoRI insert was then cloned into the P. pastoris expression incubated at 378C. All recombinant gzms used were produced in P.
pastoris. The recombinant enzymes were purified on Accell plusvector pPIC9 (Invitrogen). After completely confirming the insert
sequence in pPIC9, this vector was electroporated into GS115, and cation exchange resin (Waters), dialyzed at 48C against 100 volumes
of HE buffer, and quantitated using the BCA Protein Assay Reagentthe resulting His1 clones were selected and induced with methanol
exactly as described for the production of recombinant mouse (Pierce). Procedures employed for standard lytic assays were fol-
lowed to determine percent specific 125IUdR release. Target cellsgzmB. Supernatants of the induced His1 clones were tested for
tryptase activity on a daily basis, and a clone with a high level of incubated in HE buffer alone served as spontaneous controls. The
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addition of recombinant gzms at concentrations ranging from 2.5 Graubert, T.A., DiPersio, J.F., Russell, J.H., and Ley, T.J. (1997).
Perforin/granzyme-dependent and independent mechanisms areng/ml to 10.0 ng/ml had no effect on percent specific release values
both important for the development of graft-versus-host diseasemeasured in the spontaneous controls.
after murine bone marrow transplantation. J. Clin. Invest. 100,
904±911.In Vivo Cytotoxicity Assays
Hampson, I.N., Hampson, L., Pinkoski, M., Cross, M., Heyworth,CD81 T cells present in mesenteric lymph nodes of wild-type,
C.M., Bleackley, R.C., Atkinson, E., and Dexter, T.M. (1997). Identifi-gzmA2/2, gzmB2/2, gzmA2/2 3 gzmB2/2, or perforin2/2 mice were
cation of a serpin specifically expressed in multipotent and bipotentpurified as described (Graubert et al., 1997). Bone marrow cells (2 3
hematopoietic progenitor cells and in activated T cells. Blood 89,106 per recipient mouse) from (B6.C-H-2bm1 3 129/SvJ) F1 hosts
108±118.were prepared and infused intravenously with 1.5 3 105 CD81 T
cells into irradiated hosts as described (Graubert et al., 1996). Harris, J.L., Peterson, E.P., Hudig, D., Thornberry, N.A., and Craik,
C.S. (1998). Definition and redesign of the extended substrate speci-
ficity of granzyme B. J. Biol. Chem. 273, 27364±27373.Acknowledgments
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